Curcumin Biomarkers

This study has been completed.
Information provided by (Responsible Party):
University of North Carolina, Chapel Hill Identifier:
First received: April 6, 2011
Last updated: February 6, 2013
Last verified: January 2013
Colorectal cancer is a major problem in the United States and other developed countries. A safe and effective chemopreventive agent could reduce the burden of colorectal neoplasia. Curcumin, is a product that is derived from Curcuma longa. It has been used for thousands of years as a traditional remedy. Curcumin blocks a number of targets involved in tumor initiation, promotion, and progression, and is considered a promising chemopreventive agent. The investigators propose to enroll 40 patients after screening colonoscopy who will have rectal biopsies at baseline and after 4 weeks of curcumin 4 grams per day. The investigators will use microarray analysis to identify genes that are modified by curcumin that could be used as biomarkers in future chemoprevention studies. The study will also evaluate tolerability and toxicity.

Condition Intervention Phase
Colorectal Cancer
Drug: Curcumin C3 tablet
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Curcumin Chemoprevention of Colorectal Neoplasia

Resource links provided by NLM:

Further study details as provided by University of North Carolina, Chapel Hill:

Primary Outcome Measures:
  • Gene expression [ Time Frame: 30 days ] [ Designated as safety issue: No ]
    Change in gene expression

  • Ribonucleic acid (RNA) level [ Time Frame: 30 days ] [ Designated as safety issue: No ]
    Transcript level as mRNA copies per cell

  • Apoptosis [ Time Frame: 30 days ] [ Designated as safety issue: No ]
    Immunohistochemistry (IHC) signal as intensity and proportion of cells stained

Secondary Outcome Measures:
  • Number of Participants with Adverse Events [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]

Enrollment: 40
Study Start Date: November 2010
Study Completion Date: January 2013
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Curcumin
4g Curcumin C3 tablet daily
Drug: Curcumin C3 tablet
4 grams Curcumin C3 tablet daily x30 days


Ages Eligible for Study:   40 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age 40 - 80.
  2. A willingness to follow the study protocol, as indicated by provision of informed consent to participate
  3. Good general health

Exclusion Criteria:

  1. Familial colorectal cancer syndromes (e.g. Hereditary Non-Polyposis Colon Cancer, Familial Adenomatous Polyposis)
  2. Ulcerative colitis or Crohn's disease.
  3. History of large bowel resection for any reason
  4. Diagnosed narcotic or alcohol dependence
  5. Unwillingness to forgo curcumin/turmeric-containing supplements during the trial or consumption of curry/turmeric at meals > 3 times a week.
  6. Allergy to turmeric/curcumin.
  7. Women with childbearing potential who do not agree to practice effective birth control.
  8. Individuals with creatinine, AST or ALT above 1.5 times the upper limit of normal at baseline.
  9. Personal or inherited bleeding disorders or therapeutic anti-coagulation with warfarin.
  10. Women who are pregnant or nursing.
  11. Individuals who have taken antibiotics within the three months prior to enrollment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01333917

United States, North Carolina
UNC Department of Family Medicine
Chapel Hill, North Carolina, United States, 27599
Sponsors and Collaborators
University of North Carolina, Chapel Hill
Principal Investigator: Gary N Asher, MD, MPH University of North Carolina, Chapel Hill
  More Information

Responsible Party: University of North Carolina, Chapel Hill Identifier: NCT01333917     History of Changes
Other Study ID Numbers: 10-1524 
Study First Received: April 6, 2011
Last Updated: February 6, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by University of North Carolina, Chapel Hill:
Colorectal Cancer

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms by Site
Rectal Diseases
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antineoplastic Agents
Antirheumatic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Physiological Effects of Drugs
Sensory System Agents processed this record on May 26, 2016